Marker Therapeutics, Inc. (MRKR) is a clinical-stage biopharmaceutical company focused on developing multi-antigen recognizing T cell (MAR-T) therapies, formerly known as multiTAA-specific T cells, for cancer treatment. The company leverages its MAR-T cell platform to develop product candidates targeting multiple tumor-associated antigens. Marker maintains a key collaboration with Baylor College of Medicine (BCM) to support its research and development programs.
Q2 FY2026 — expected 2026-08-15
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-18 | 2025-12-31 | 0001104659-26-031274 | EDGAR | 73K words |
| 2025-03-31 | 2024-12-31 | 0001410578-25-000549 | EDGAR | — |
| 2024-03-26 | 2023-12-31 | 0001410578-24-000297 | EDGAR | — |
| 2023-03-22 | 2022-12-31 | 0001410578-23-000324 | EDGAR | — |
| 2022-03-17 | 2021-12-31 | 0001410578-22-000418 | EDGAR | — |
| 2021-03-09 | 2020-12-31 | 0001104659-21-033855 | EDGAR | — |
| 2020-03-12 | 2019-12-31 | 0001104659-20-032463 | EDGAR | — |
| 2019-03-15 | 2018-12-31 | 0001144204-19-014350 | EDGAR | — |
| 2018-03-23 | 2017-12-31 | 0001144204-18-016734 | EDGAR | — |
| 2017-03-14 | 2016-12-31 | 0001144204-17-014490 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-13 | 2025-09-30 | 0001104659-25-111502 | EDGAR | 21K words |
| 2025-08-14 | 2025-06-30 | 0001410578-25-001826 | EDGAR | — |
| 2025-05-15 | 2025-03-31 | 0001410578-25-001342 | EDGAR | — |
| 2024-11-14 | 2024-09-30 | 0001410578-24-001978 | EDGAR | — |
| 2024-08-14 | 2024-06-30 | 0001410578-24-001454 | EDGAR | — |
| 2024-05-15 | 2024-03-31 | 0001410578-24-000865 | EDGAR | — |
| 2023-11-09 | 2023-09-30 | 0001410578-23-002307 | EDGAR | — |
| 2023-08-14 | 2023-06-30 | 0001410578-23-001875 | EDGAR | — |
| 2023-05-15 | 2023-03-31 | 0001410578-23-001217 | EDGAR | — |
| 2022-11-10 | 2022-09-30 | 0001410578-22-003131 | EDGAR | — |
| 2022-08-11 | 2022-06-30 | 0001410578-22-002292 | EDGAR | — |
| 2022-05-13 | 2022-03-31 | 0001410578-22-001389 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-19 | 0001104659-26-031309 | EDGAR | 3K words |
| 2026-02-09 | 0001104659-26-012063 | EDGAR | — |
| 2025-11-14 | 0001104659-25-111940 | EDGAR | — |
| 2025-11-05 | 0001104659-25-106669 | EDGAR | — |
| 2025-10-06 | 0001104659-25-096935 | EDGAR | — |
| 2025-08-26 | 0001104659-25-082783 | EDGAR | — |
| 2025-08-12 | 0001104659-25-076834 | EDGAR | — |
| 2025-06-17 | 0001104659-25-060092 | EDGAR | — |
| 2025-06-09 | 0001104659-25-057836 | EDGAR | — |
| 2025-05-20 | 0001104659-25-050771 | EDGAR | — |
330 total filings indexed. 298 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001094038 |
| Ticker | MRKR |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.markertherapeutics.com |
| Listed | 1998-01-07 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report